US government

Emergent Revises Upward 2010 Financial Forecast

Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million

Submitted by admin on Tue, 08/03/2010 - 10:35. categories [ ]

Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax

ROCKVILLE, Md., Jul 14, 2010

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax(R) (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company’s large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

Submitted by admin on Thu, 07/15/2010 - 15:53. categories [ ]